LGND
Ligand Pharmaceuticals Incorporated
NASDAQ · USHealthcareBiotechnology
$293.99-3.10%
Price as of Jul 20, 2026
LGND profitability
Ligand Pharmaceuticals Incorporated profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 98.6%
- EBITDA margin
- 81.0%
- EBIT margin
- 36.7%
- Net margin
- 55.9%
- Free cash flow margin
- 44.8%
Returns
- Return on equity
- 15.4%
- Return on assets
- 10.0%
- Return on invested capital
- 7.0%
- Asset turnover
- 0.18x
Cash efficiency
- Cash from operations
- $123.4M
- Cash per share
- $39
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.